influenza (H3) 15.4% (33.3% non-typeable H1), B-hemolytic Streptococcus Group A 1.5% and Neisseria meningitidis 0.7%. Seventy-one percent of cases had complications (pleural effusion 63%, necrotizing pneumonia 11.1%, pneumothorax 8.1%, lung abscess 3.7%, atelectasis 0.7%). Other clinical manifestations combined with CAPB were: sepis 20%, cellulitis/abscess 9.6%, arthritis 6.7%, meningitis 5.9% and osteomyelitis 2.8%. Considering this was the predominant radiological pattern for all agents in 88.1%. Lethality rate was 3%. Sp was more associated with age ≥24 months [OR 2.78 (1.18–6.64)] and Hi was more associated with age <24 months [OR 4.76 (1.62–14.31)]. Complications were significantly higher among Sa pneumoniae cases. Children with CAPB and sepis was on average had higher lethality [OR 13.38 (1.14–355.45) and OR 17.71 (1.46–223.73)], respectively.

Conclusion. After PCV13 introduction Sp was the most common organism causing CAPB, mainly in ≥24 months of age. Sa followed in frequency with high mortality. CAPB combined with other clinical manifestations were more associated with lethality.

Disclosures. All authors: No reported disclosures.

1461. Non-Invasive Pneumococcal Pneumonia in the United States, 2013–2014
Almea Matakonck, MD1; Ryan Gierke, MPH2; Nong Shang, PhD3; James Watt, MD, MPH4; Neisha Allen, MPH5; Susan Petit, MPH6; Monica M. Farley, MD, FIDSA7; Lee H. Harrington, MD8; Katherine Schleiss, MPH9; Kari Burzlaff, MPH8; Ann Thomas, MD, MPH10; William Schaffner, MD, FIDSA, FSHEA11; Gayle E. Langley, MD, MPH12 and Tamara Pilishvili, MPH13;3; Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, 3Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, 1California Department of Public Health, Richmond, California, 4Colorado Department of Public Health and Environment, Denver, Colorado, 5Connecticut Department of Public Health, New Haven, Connecticut, 6Department of Medicine, Emory University School of Medicine and Atlanta VA Medical Center, Atlanta, Georgia, 7Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 8Infectious Disease Epidemiology Prevention & Control, Minnesota Department of Health, St. Paul, Minnesota, 9New York State Department of Health, Buffalo, New York, 10Oregon Public Health Division, Portland, Oregon, 11Vanderbilt University School of Medicine, Nashville, Tennessee
Session: 147. Respiratory Infections: CAP
Friday, October 5, 2018: 12:30 PM
Background. Surveillance for pneumococcal pneumonia (PP) is challenging due to limitations of available diagnostic tests. Previous studies estimated PP from all-cause pneumonia or invasive pneumonia (i.e., positive S. pneumoniae sterile site culture). In 2014, pneumococcal conjugate vaccine (PCV13) was recommended for adults ≥26 years old. We established population-based surveillance for non-invasive pneumococcal pneumonia (NPP) to estimate disease burden and establish a baseline for PCV13 impact evaluation.

Methods. We defined a case as clinically or radiographically confirmed pneumococcal pneumonia, positive pneumococcal urine antigen test (UAT), and no evidence of invasive pneumococcal disease in a hospitalized adult ≥18 years old residing in our surveillance areas, which overlapped with active bacterial core surveillance areas representing 17,000,000 adults across the United States. We estimated NPP incidence (cases/100,000 population) using 2013 Census data and applying PCV13 impact to adults ≥26 years old. We estimated population-based surveillance for non-invasive pneumococcal pneumonia to (1) estimate disease burden and establish a baseline for non-invasive pneumococcal pneumonia (NPP) to estimate disease burden and establish a baseline for PCV13 impact evaluation.

Results. In 2013–2014, 1,854 patients met our case definition; median age was 65 years (range 18–102). On average, patients were diagnosed on hospital Day 1 (range 3–30 days) and hospitalized for 5 days (range <1–152). Adjusting the crude incidence of 610,000 (reported UAT cases) by factors 1 and 2, we estimated NPP incidence to be 99/100,000 population.

Clinical Description of Patients with UAT Confirmed NPP (N=1,854)

| Age ≥65 years | 953 (51) |
| Radiographically confirmed pneumonia | 1,604 (87) |
| Intensive care unit admission | 653 (35) |
| Died | 119 (6) |
| Underlying medical condition | 1,752 (95) |
| Immunocompromising condition | 764 (41) |
| Smoke tobacco | 677 (37) |

Conclusion. Our population-based surveillance system allows us to estimate the incidence of laboratory confirmed NPP. Given imperfect UAT sensitivity, this is an underestimate. A more sensitive and serotype-specific UAT could provide improved detection and understanding of NPP. Nonetheless, NPP surveillance allows us to better understand populations at risk for NPP and establish a baseline to evaluate impact of PCV13 on NPP incidence among adults.

Disclosures. L. H. Harrison, Merck: sponsored symposium on pneumococcal vaccines, Marshall; W. Schaffner, Merck: Member, Data Safety Monitoring Board, Consulting fee; Pfizer: Member, Data Safety Monitoring Board, Consulting fee; Dynavax: Consultant, Consulting fee; Seqirus: Consultant, Consulting fee; SutroVax: Consultant, Consulting fee; Shionogi: Consultant, Consulting fee.

1462. Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia Who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
Thomas Lodise, PharmD, PhD1; and Ken LaPensee, PharmD, PhD2; 1Albany College of Pharmacy and the Health Sciences, Albany, New York, 2Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania
Session: 147. Respiratory Infections: CAP
Friday, October 5, 2018: 12:30 PM

Background. Given the disparity in cost between inpatient and outpatient care, the IDSA/ATS community-acquired pneumonia (CAP) guidelines recommend use of site-of-care severity of illness indicators to identify CAP patients who may be candidates for outpatient treatment. Despite this level 1 recommendation, there are limited data on US hospital community-acquired bacterial pneumonia (CAPB) admissions patterns stratified by Pneumonia Severity Index (PSI) score and presence of comorbidities. This study described hospitalization and length of stay (LOS) patterns among adult patients with CAPB who received ceftriaxone (CTX) and a macrolide (M) at admission in the MedAssets database. The primary objective was to quantify the proportion of admissions and associated hospital LOS among “low-risk” patients (PSI score ≤ 90) where outpatient or short admission is advocated.

Methods. A retrospective study of patients hospitalized for CAPB and in the MedAssets database during 2012–2015 was performed. Inclusion criteria: (1) age ≥18 years, (2) a primary diagnosis for CAPB, (3) received CTX and a M on hospitalization Day 1 or 2, and (3) ≥21-year enrollment before the index date. For patients with multiple hospitalizations for CAPB during the study period, only the first episode was considered. The distribution of hospital admissions was stratified by PSI categories and Charlson Comorbidity Index (CCI). Both PSI and CCI were derived from diagnosis codes. Hospital LOS and mortality rates were tabulated across resulting PSI-CCI categories.

Results. During the study period, 68,254 patients met inclusion criteria. Among hospitalized CAPB patients, 35% had a PSI score ≤70 and 33% had a PSI score between 71–90. The mean LOS for patients with a PSI score ≤70 and 71–90 ranged between 5.2 and 6.6 days, depending on CCI score. Mortality was less than 0.5% for patients with PSI ≤70 and 1.4% for patients with a 71–90 PSI score.

Conclusion. More than two-thirds of hospitalized CAPB patients who received CTX and an M had a PSI score ≤90. On average, hospital LOS was 5–6 days for CAPB patients with PSI ≤90. These findings reflect the critical need to identify outpatient treatments that can effectively reduce hospital admissions.

Disclosures. T. Lodise, Paratek Pharmaceuticals: Consultant and Scientific Advisor, Consulting fee. K. LaPensee, Paratek Pharmaceuticals: Employee, Salary.

1463. Comparative Evaluation of Adverse Tendon Events Between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin Among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia
Nimish Patel, PharmD, PhD1; Jeffrey Clark, PharmD2; Nicholas Stornelli, PharmD3; Uma Belloret, PharmD1 and Thomas P. Lodise, PharmD, PhD2; 1Albany College of Pharmacy & Health Sciences, Albany, New York, 2Albany College of Pharmacy, Albany, New York
Session: 147. Respiratory Infections: CAP
Friday, October 5, 2018: 12:30 PM

Background. Fluoroquinolones (FQs) are used commonly for patients with community acquired bacterial pneumonia (CAPB). A recent FDA Drug Safety Communication strengthened labeling regarding tendinopathy/tendon rupture for FQs. The data prompting this change lacked a comparator group of patients using other antibiotics, like ceftriaxone/azithromycin (CTX-AZ) for similar indications. The objectives of this study were to compare the incidence of adverse tendon events (TE) between FQ and CTX-AZ among patients with CAPB and determine if FQ treatment is independently associated with TE.

Methods. A retrospective cohort study was performed among patients in the Upstate New York Veterans’ Healthcare Administration. Inclusion criteria: (1) age ≥18 years, (2) diagnosis of CAPB (ICD9 code with manual confirmation) from January 2014 to December 2015, (3) receipt of IV/oral FQ or CTX-AZ ≥1 day, and (4) treatment initiated as inpatient. Data were collected from patient medical records. Occurrence of TE was defined using a natural word search algorithm of patients’ clinical progress notes within 90 days of starting FQ or CTX-AZ therapy. Search terms were: tendinopathy, tendon pain, tendon rupture, tendinitis, and Achilles heel pain/tear/torn/rupture. Classification and regression tree (CART) was used to identify breakpoints in continuous variables associated with TE.

Results. There were 379 FQ and 274 CTX-AZ recipients. Mean ± standard deviation (SD) ages for FQ and CTX-AZ recipients were, 73.0 ± 12.7 vs. 72.8 ± 12.7 years, respectively. Mean (SD) APACHE-II was significantly higher for FQ than CTX-AZ recipients, 10.2 ± 5.1 vs. 8.5 ± 3.6, respectively (P = 0.001). Residence in the intensive care unit at start of therapy did not differ (FQ: 11.6% vs. CTX-AZ: 10.2%, P = 0.58). The incidence of TE did not differ between groups (FQ: 9/379 [2.4%] vs. CTX-AZ: 23/274 [8.4%]; P = 0.18). In multivariate analyses (figure), treatment was not independently associated with TE (aOR: 1.78, 95% confidence interval: 0.51–6.21, P = 0.37) after adjustment for treatment duration, APACHE-II, age ≥75 years and BMI ≥22.7.